<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recognition and management of allergic disease during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recognition and management of allergic disease during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Recognition and management of allergic disease during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Schatz, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnancy may be complicated by new-onset or preexisting allergic disease, including rhinitis, urticaria, angioedema, or atopic dermatitis (AD). In contrast with asthma in pregnancy, relatively few studies have examined the management of other allergic disorders in pregnant persons.</p><p>This topic reviews the recognition and management of rhinitis, urticaria, angioedema, and AD in pregnancy as well as general principles of medication use during pregnancy. The diagnosis and management of asthma in pregnancy, anaphylaxis in pregnancy, the various dermatoses of pregnancy, and the management of allergic rhinitis in nonpregnant patients are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/554.html" rel="external">"Management of asthma during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h2">General approach to treating allergy in pregnancy</span><span class="headingEndMark"> — </span>In any form of allergic disease, a primary element of management is avoidance of the culprit allergen when possible. Allergen avoidance is particularly important during pregnancy because the use of systemic medications should be minimized, if possible.</p><p>Females with significant allergic disease should ideally be evaluated <strong>before</strong> they become pregnant so that any skin testing, challenge procedures, or other exposures that might be necessary for definitive diagnosis can be safely performed. This is especially important for females with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Allergies to medications that may be needed during pregnancy, such as local anesthetics or drugs used in general anesthesia. (See  <a class="medical medical_review" href="/d/html/2081.html" rel="external">"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergies for which there are definitive treatments, such as stinging insect venom (yellowjackets, bees, fire ants, others). Some patients with these allergies are candidates for venom immunotherapy, which can be continued during pregnancy but should not generally be initiated in a patient who is already pregnant. (See  <a class="medical medical_review" href="/d/html/4090.html" rel="external">"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action", section on 'Pregnant women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any female who has experienced anaphylaxis. Anaphylaxis can be devastating to both the mother and fetus. As a result, it is imperative to prevent a recurrence during pregnancy. (See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Systems for assessing drug safety in pregnancy</span><span class="headingEndMark"> — </span>When considering the use of medications in a pregnant person, the potential risk of a drug must be balanced against the effects of untreated disease. Despite the potential for harm, few drugs have been proven harmful in pregnancy, and fewer than 1 percent of congenital malformations can be attributed to drugs [<a href="#rid1">1</a>]. However, statistical and ethical considerations make it unlikely that any drug will ever be "proven safe." A general discussion of the assessment of the risk of medication use based upon animal and human studies is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Safety of selected common medications used transiently in pregnancy'</a>.)</p><p>Many allergic disorders can be managed with topical medications, including nasal sprays, eye drops, and topical lotions and creams. These preparations allow the drug to be concentrated at the site of inflammation so that less total drug is required to obtain clinical benefit. However, not all topical preparations are considered appropriate for use in pregnancy. (See <a class="local">'Anaphylaxis'</a> below and <a class="local">'Rhinitis'</a> below and <a class="local">'Urticaria and angioedema'</a> below and <a class="local">'Atopic dermatitis'</a> below.)</p><p>The US Food and Drug Administration (FDA) previously established five categories (A, B, C, D, and X) to describe a drug's potential for causing adverse effects during pregnancy and mandated that drugs introduced after 1980 be classified into one of these categories in the package insert [<a href="#rid2">2</a>]. The categories were based upon the results of animal studies, human data, and consideration of whether the benefit of the drug's use during pregnancy outweighs the risk. In 2015, the US FDA began overseeing the phase-out of pregnancy risk categories from prescription drug labeling and began requiring information from available human and animal studies of known or potential maternal or fetal adverse reactions and dose adjustments needed during pregnancy and the postpartum period. Additional information is available on the US FDA website [<a href="#rid3">3</a>]. A general discussion of the assessment of the risk of medication use based upon animal and human studies is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/554.html" rel="external">"Management of asthma during pregnancy", section on 'Assessing drug safety in pregnancy'</a>.)</p><p>In the interim, it is helpful for clinicians to be aware of the categories assigned to allergy medications within the older system. There are no allergy medications that meet the requirements for category A (adequately controlled studies show no risk). Most category B drugs are labeled as such because of reassuring animal studies without "adequate and controlled" human data. One may wish to choose a class B versus a class C drug (risk cannot be ruled out) among equally effective alternatives due to the reassuring animal studies.</p><p>Among commonly used allergy medications, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> (inhaled and intranasal), <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> sodium, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="9443" href="/d/drug information/9443.html" rel="external">levocetirizine</a>, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, and <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> were assigned category B.</p><p class="headingAnchor" id="H5"><span class="h1">ANAPHYLAXIS</span><span class="headingEndMark"> — </span>Anaphylaxis is uncommon during pregnancy. However, it is important to recognize it rapidly and treat it effectively as the maternal hypoxia and hypotension that can result may be catastrophic to both mother and fetus. <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is the treatment of choice in pregnancy. (See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">RHINITIS</span><span class="headingEndMark"> — </span>Clinical experience suggests that the most common causes of nasal symptoms necessitating treatment during pregnancy are [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy rhinitis</p><p class="bulletIndent1"><span class="glyph">●</span>Allergic rhinitis</p><p class="bulletIndent1"><span class="glyph">●</span>Rhinitis medicamentosa</p><p class="bulletIndent1"><span class="glyph">●</span>Sinusitis</p><p></p><p>Other types of rhinitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/7533.html" rel="external">"An overview of rhinitis"</a>.)</p><p class="headingAnchor" id="H2251392"><span class="h2">Nondrug therapies</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions may be considered first in pregnant persons with rhinitis symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">Saline</a><strong> nasal sprays or nasal irrigation</strong> – Nasal irrigation is a nonpharmacologic intervention that is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed [<a href="#rid5">5</a>]. A variety of devices, including bulb syringes and bottle sprayers, may be used to perform nasal lavage  (<a class="graphic graphic_table graphicRef71059" href="/d/graphic/71059.html" rel="external">table 1</a>). Patients should use at least 200 mL in each nostril. This can be performed daily or only as needed for intermittent symptoms [<a href="#rid6">6</a>]. In a randomized trial of pregnant persons, nasal saline irrigation was shown to be beneficial for treatment of allergic rhinitis [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – Regular physical exercise can help by causing physiologic nasal vasoconstriction [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal dilator strips</strong> – Adhesive strips that mechanically hold the nasal valves open (external nasal dilators) are available over the counter and can be useful at night [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevation of the head of the bed by 30 to 45 degrees</strong> – Placing bricks or other objects under the legs of the bed is more effective than using extra pillows [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Pregnancy rhinitis</span><span class="headingEndMark"> — </span>Pregnancy normally induces hyperemia and edema of the nasal mucosa. This and other pregnancy-related changes in the upper respiratory tract are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4788.html" rel="external">"Maternal adaptations to pregnancy: Dyspnea and other physiologic respiratory changes", section on 'Physiologic pulmonary changes in pregnancy'</a>.)</p><p>Twenty to 30 percent of pregnant persons develop symptomatic nasal congestion during pregnancy, a condition called pregnancy rhinitis (or rhinitis of pregnancy) [<a href="#rid12">12,13</a>]. Pregnancy rhinitis may be defined as nasal symptoms during pregnancy lasting six or more weeks without other signs of respiratory tract infection and with no known allergic cause, disappearing completely within two weeks after delivery [<a href="#rid14">14</a>]. Patients complain of persistent nasal congestion, accompanied by watery or viscous clear nasal secretions [<a href="#rid15">15</a>]. Nasal congestion can lead to mouth breathing at night and reduced quality of sleep. The other causes of rhinitis listed above must be excluded [<a href="#rid16">16</a>].</p><p>The pathophysiology of pregnancy rhinitis is not known. In the past, it was attributed to changes in estrogen and/or progesterone, although there is little specific evidence to support this assertion [<a href="#rid17">17</a>]. Smoking and allergic sensitization to dust mites were identified as risk factors for the development of pregnancy rhinitis in one study [<a href="#rid18">18</a>]. However, neither asthma nor hay fever is more common among females who develop pregnancy rhinitis.</p><p class="headingAnchor" id="H8"><span class="h3">Management</span><span class="headingEndMark"> — </span>Pregnancy rhinitis does not usually require therapy nor does it respond well to medications. In those who seek specific treatment, nonpharmacologic measures are suggested. (See <a class="local">'Nondrug therapies'</a> above.)</p><p>Several medications have been studied in pregnancy rhinitis, although none have demonstrated clear efficacy:</p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal corticosteroid sprays were <strong>not</strong> beneficial for pregnancy rhinitis in a randomized trial of 53 females [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">Pseudoephedrine</a> is also occasionally used for severe pregnancy rhinitis, although oral vasoconstrictors should be avoided in the first trimester and in females with hypertension. (See <a class="local">'Decongestants'</a> below.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Effect of pregnancy on preexisting rhinitis</span><span class="headingEndMark"> — </span>Preexisting rhinitis may worsen, improve, or remain unchanged during pregnancy [<a href="#rid4">4</a>]. These trends are similar to those seen with asthma, and one study found concordance between the course of asthma and that of rhinitis during pregnancy [<a href="#rid20">20</a>]. This suggests that mechanistic factors involved in both diseases may be similarly altered during pregnancy.</p><p>Data suggest that rhinitis does not directly affect pregnancy outcome [<a href="#rid21">21</a>]. However, uncontrolled rhinitis can indirectly affect pregnancy by impacting gestational nutrition, sleep, or stress. In addition, uncontrolled rhinitis may be a cause of snoring, which may increase the risk of gestational hypertension, preeclampsia, and intrauterine growth retardation, although not all studies have confirmed this association [<a href="#rid22">22-24</a>].</p><p>Uncontrolled rhinitis may also predispose to sinusitis or exacerbate coexisting asthma during pregnancy. In a study of 218 pregnant women with asthma [<a href="#rid25">25</a>], the presence and severity of rhinitis was associated with the level of asthma control. Thus, appropriate management of rhinitis during pregnancy can help avoid exposures to other medications, such as antibiotics and oral glucocorticoids.</p><p class="headingAnchor" id="H10"><span class="h2">Allergic rhinitis/conjunctivitis</span><span class="headingEndMark"> — </span>Allergic rhinitis is usually preexisting, although it may develop or be recognized for the first time during pregnancy. Patients with allergic rhinitis often report prominent sneezing, nasal pruritus, and watery rhinorrhea, and some have concomitant ocular itching and irritation. Common triggers for allergic rhinitis include dust mites, animal danders, molds, and pollens. (See  <a class="medical medical_review" href="/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>The management of allergic conjunctivitis during pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/90512.html" rel="external">"Allergic conjunctivitis: Management", section on 'Pregnant patients'</a>.)</p><p class="headingAnchor" id="H279008208"><span class="h3">Evaluation during pregnancy</span><span class="headingEndMark"> — </span>Although allergy skin testing is considered extremely safe, there are rare, highly sensitive patients in whom skin testing can induce systemic allergic reactions. Thus, in vitro tests are preferred during pregnancy for identification of specific inhalant allergens to which a previously untested patient is sensitive.</p><p>In vitro tests for allergen-specific immunoglobulin E (IgE) are widely available, and the use of these tests in the diagnosis of allergic rhinitis is reviewed in detail elsewhere. Alternatively, therapy can be initiated empirically, even if the causative allergens are not known. (See  <a class="medical medical_review" href="/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis", section on 'Serum tests for allergy'</a>.)</p><p class="headingAnchor" id="H279008214"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>Our approach to the management of allergic rhinitis is described below and summarized in an algorithm  (<a class="graphic graphic_algorithm graphicRef134600" href="/d/graphic/134600.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Allergen avoidance (if the causative allergens are known) and nonpharmacologic therapies should be recommended initially and may be adequate for mild symptoms. (See <a class="local">'Nondrug therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For intermittent or mild symptoms despite nondrug measures, we consider a second-generation antihistamine as needed or regularly (eg, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a> [10 mg once daily], <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> [10 mg once daily], or <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a> [180 mg once daily]) all have reassuring safety data. <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">Cromolyn</a> sodium nasal spray is another option, although it requires frequent dosing. (See <a class="local">'Oral antihistamines'</a> below and <a class="local">'Cromolyn sodium nasal spray'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For moderate-to-severe symptoms, based on human data, we favor <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a>, or <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> nasal spray as an initial therapy and add a second-generation antihistamine for additional symptom control, if needed. (See <a class="local">'Corticosteroid nasal sprays'</a> below.)</p><p></p><p class="headingAnchor" id="H279008221"><span class="h3">Medication choices</span><span class="headingEndMark"> — </span>The various therapies for allergic rhinitis and their safety in pregnancy are reviewed in this section. Our approach is discussed above. (See <a class="local">'Our approach'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h4">Cromolyn sodium nasal spray</span><span class="headingEndMark"> — </span>Intranasal <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> sodium may be considered a first-line therapy for mild allergic rhinitis in pregnancy because of its excellent safety profile. Cromolyn sodium is minimally absorbed into the systemic circulation when applied to a mucosal surface [<a href="#rid26">26</a>]. Three human studies of over 600 pregnancies, including first trimester use, failed to detect any increased risk for congenital defects with inhaled cromolyn sodium, although there are no safety data specific to nasal or ophthalmic preparations [<a href="#rid27">27</a>].</p><p>Dosing of intranasal <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> is one spray per nostril up to six times daily. The utility of cromolyn is limited by the need for frequent dosing and by lower efficacy compared with newer therapies. However, the safety of this therapy and its availability without a prescription (ie, over the counter) make it a reasonable initial choice for some patients.</p><p class="headingAnchor" id="H12"><span class="h4">Corticosteroid nasal sprays</span><span class="headingEndMark"> — </span>Intranasal corticosteroids are highly effective for allergic rhinitis and are particularly helpful for alleviating nasal congestion and postnasal drip. Corticosteroid sprays are the treatment of choice for moderate-to-severe allergic rhinitis during pregnancy  (<a class="graphic graphic_table graphicRef99900" href="/d/graphic/99900.html" rel="external">table 2</a>). The lowest effective dose should be used during pregnancy.</p><p>The safety of corticosteroid nasal sprays in pregnancy has been based on reassuring data from glucocorticoid inhalers for asthma [<a href="#rid28">28</a>], which deliver higher doses than nasal sprays. The overall safety of intranasal corticosteroids in pregnancy was confirmed by a 2016 study of over 140,000 pregnant persons, of whom 2502 were exposed to these medications during the first trimester [<a href="#rid29">29,30</a>]. There was no increase in overall rates of major congenital malformations or spontaneous abortions among exposed patients. The only intranasal corticosteroid for which there was a signal of potential concern was <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a>, which was associated with malformations of the respiratory system specifically (adjusted odds ratio [OR] 2.71, 95% CI 1.11-6.64). This was based upon a small number of cases: two cases of unspecified congenital malformations of the respiratory tract, one case of congenital malformations of the larynx, two cases of trachea and bronchus abnormalities, and one case of choanal atresia. Other agents were not associated with an excess of any specific abnormalities. Some clinicians choose <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> if starting intranasal corticosteroids for the first time during pregnancy since it was classified as a category B drug in the previous US Food and Drug Administration (FDA) system, based on reassuring data on inhaled budesonide from the population-based Swedish Medical Birth Registry, whereas most of the other agents were category C [<a href="#rid31">31</a>]. The 2016 study also provided reassuring data about use of intranasal <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> or <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> in the first trimester as these agents were more commonly used in the study population and were not associated with adverse outcomes [<a href="#rid29">29,30</a>]. (See <a class="local">'Systems for assessing drug safety in pregnancy'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h4">Oral antihistamines</span><span class="headingEndMark"> — </span>Oral antihistamines are less effective for the treatment of allergic rhinitis compared with intranasal corticosteroids, particularly for the relief of nasal congestion and postnasal drip. Several studies have evaluated the safety of antihistamines during pregnancy [<a href="#rid32">32-36</a>]. Most pregnant persons who require antihistamines are most appropriately treated with a second-generation agent because these drugs are less sedating and have fewer cholinergic side effects compared with first-generation agents.</p><p class="bulletIndent1"><span class="glyph">●</span>Among second-generation antihistamines (eg, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a> [10 mg once daily] or <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> [10 mg once daily]) may be considered the second-generation antihistamines of choice in pregnancy. There are reassuring human data for each of these drugs in a large number of pregnant patients, and they were rated category B [<a href="#rid36">36</a>]. <a class="drug drug_general" data-topicid="9443" href="/d/drug information/9443.html" rel="external">Levocetirizine</a> is also a category B drug, but there are few published human data. Data on use of <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a> in pregnancy are also reassuring [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-generation agents are widely available, inexpensive, and can be useful on an as-needed basis and/or before bed. Among the first-generation agents, <a class="drug drug_general" data-topicid="8860" href="/d/drug information/8860.html" rel="external">chlorpheniramine</a> has been recommended as the first-generation antihistamine of choice for use during pregnancy because it has been used for decades, and animal and human data are reassuring [<a href="#rid32">32</a>]. The dosing of chlorpheniramine is 4 mg every four to six hours. Sustained-release formulations are available (eg, 8 mg up to three times daily and 12 mg twice daily). Dosing should not exceed 24 mg per day.</p><p></p><p class="headingAnchor" id="H14"><span class="h4">Antihistamine nasal sprays</span><span class="headingEndMark"> — </span>Human safety data are not available for <a class="drug drug_general" data-topicid="8798" href="/d/drug information/8798.html" rel="external">azelastine</a> or <a class="drug drug_general" data-topicid="10177" href="/d/drug information/10177.html" rel="external">olopatadine</a> nasal sprays, although animal studies are reassuring [<a href="#rid21">21</a>]. Until more information is available, we would suggest avoiding these medications during pregnancy unless a patient was uniquely responsive to one of them prior to pregnancy.</p><p class="headingAnchor" id="H15"><span class="h4">Decongestants</span><span class="headingEndMark"> — </span>Decongestants are vasoconstrictors that are available as both oral preparations and nasal sprays. It is not known whether or not this group of drugs crosses the placenta [<a href="#rid38">38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal decongestants</strong> – Decongestant nasal sprays can be used <strong>very briefly</strong> (eg, three days or less) for temporary relief of severe nasal congestion during pregnancy. Some reassuring human data exist for intranasal <a class="drug drug_general" data-topicid="10186" href="/d/drug information/10186.html" rel="external">oxymetazoline</a> [<a href="#rid39">39,40</a>], although one study found possible associations between oxymetazoline or <a class="drug drug_general" data-topicid="106757" href="/d/drug information/106757.html" rel="external">xylometazoline</a> and several malformations [<a href="#rid38">38</a>]. Patients should be warned about dependence with prolonged use. (See <a class="local">'Rhinitis medicamentosa'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral decongestants</strong> – Oral decongestants are best avoided altogether during the first trimester because of an uncertain risk of several rare congenital anomalies [<a href="#rid38">38</a>]. <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">Pseudoephedrine</a> can be used in the second and third trimesters in females without hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pseudoephedrine</strong> – <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">Pseudoephedrine</a> is administered at a dose of 60 mg, given at a maximum frequency of four times daily, or 120 mg of the long-acting preparation given twice daily. Oral decongestants should generally be avoided during the first trimester, but, during the second and third trimesters, pseudoephedrine is the decongestant of choice in females without hypertension [<a href="#rid9">9</a>]. In the United States, increasing abuse of pseudoephedrine as a stimulant in athletics and in the illegal production of methamphetamines has led to limits of how much can be obtained over the counter, and patients must provide identification (eg, a driver's license) to purchase the drug.</p><p></p><p class="bulletIndent2">A possible association between <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> and gastroschisis (baseline incidence of 1 in 10,000 births) was found in two case-control studies [<a href="#rid38">38,41</a>]. Infant gastroschisis has also been reported with maternal phenylpropanolamine use [<a href="#rid42">42</a>], suggesting a possible drug class effect. Another abnormality associated with first-trimester pseudoephedrine use is limb reduction defects [<a href="#rid38">38</a>]. However, reassuring data on pseudoephedrine also exist. A Swedish study prospectively examined the pregnancy outcomes of 2474 females who had reported use of oral decongestants (mostly phenylpropanolamine or pseudoephedrine) in early pregnancy and 1774 females who used these medications in later pregnancy [<a href="#rid43">43</a>]. No teratogenic effects were detected in either group. In addition, the use of these medications in later pregnancy (after the first antenatal visit) was associated with lower rates of premature birth, low birth weight, small-for-date infants, and perinatal death, prompting the authors to hypothesize that rhinitis of pregnancy may be a sign of good placental function. Although these data are reassuring, they do not have adequate power to exclude an increased risk of congenital malformations due to maternal first trimester use of oral decongestants.</p><p></p><p class="bulletIndent2">Concern has also been raised regarding potential adverse effects of <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> on uteroplacental blood flow, although a single-dose study did not show any significant adverse effect [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phenylephrine</strong> – <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">Phenylephrine</a> should be avoided in pregnancy because of uncertain efficacy and questionable safety. Phenylephrine is less effective than <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> for the treatment of rhinitis symptoms and may not be superior to placebo at the 10 mg dose that is commonly available over the counter [<a href="#rid45">45-47</a>]. In addition, phenylephrine (unlike pseudoephedrine) has strong alpha-agonist properties, and uterine blood vessels selectively express alpha-adrenergic receptors [<a href="#rid48">48</a>]. Therapeutic doses of phenylephrine were shown to reduce uterine blood flow substantially in animal models [<a href="#rid49">49</a>]. Studies of congenital defects and phenylephrine exposure have identified an increased risk of endocardial cushion defect [<a href="#rid38">38,50</a>]. Despite its clear inferiority, phenylephrine had been increasingly used as a substitute for pseudoephedrine in many over-the-counter preparations in the United States because of the abuse potential of pseudoephedrine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phenylpropanolamine</strong> – Phenylpropanolamine is no longer available in the United States and many other countries due to a proposed increased risk of stroke in young females, although it is available in some parts of the world without a prescription. Its use in pregnancy is discouraged. Infant gastroschisis has been reported with maternal phenylpropanolamine use as with <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H16"><span class="h4">Antihistamines and decongestants combined</span><span class="headingEndMark"> — </span>Patients with allergic rhinitis who have prominent nasal congestion often report more relief with the combination of an antihistamine and <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> than with either drug alone. However, since pseudoephedrine should be avoided in the first trimester, it is preferable to recommend corticosteroid nasal sprays instead to such patients during pregnancy. Corticosteroid sprays provide particularly effective relief of nasal congestion. Efficacy studies of these agents are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Glucocorticoid nasal sprays'</a>.)</p><p class="headingAnchor" id="H988446622"><span class="h4">Montelukast</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">Montelukast</a> is approved for the treatment of allergic rhinitis and has reassuring animal and human gestational safety data regarding congenital malformations [<a href="#rid51">51-53</a>]. However, it is not as effective as intranasal corticosteroids [<a href="#rid54">54</a>] and should generally only be used during pregnancy for the treatment of allergic rhinitis in patients who have demonstrated substantial benefit before pregnancy or in patients with confirmed allergic rhinitis not controlled by intranasal corticosteroids and antihistamines.</p><p class="headingAnchor" id="H287121958"><span class="h3">Herbal therapies</span><span class="headingEndMark"> — </span>We suggest avoiding herbal therapies during pregnancy because, in the United States and most other countries, herbal medicines are minimally regulated and monitored for adverse events by national surveillance systems. Safety issues surrounding the use of herbal preparations are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1392.html" rel="external">"Overview of herbal medicine and dietary supplements"</a> and  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Allergen immunotherapy</span><span class="headingEndMark"> — </span>Subcutaneous allergen immunotherapy (SCIT) is <strong>not</strong> initiated during pregnancy due to the potential harm that could result if a systemic reaction or anaphylaxis were to occur. However, patients who were tolerating and deriving benefit from SCIT prior to pregnancy may continue it through pregnancy in many cases.</p><p>Considerations <strong>against</strong> beginning immunotherapy during pregnancy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The propensity for systemic reactions in that patient is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic reactions are more likely during initiation of immunotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy typically takes months to work, so the patient would not derive clinical benefit for most of the pregnancy anyway.</p><p></p><p>The continuation of SCIT during pregnancy appears to be safe, aside from the risk of systemic reactions. Two studies of 230 pregnancies in 171 women receiving inhalant allergen immunotherapy reported no increase in abortions, perinatal deaths, prematurity, toxemia, or congenital malformations in the treated patients in comparison with both a nontreated pregnant-allergic control group and to the general population [<a href="#rid2">2,31</a>]. A much larger study was also reassuring. This national Swedish cohort study identified 924,790 singleton pregnancies, among which 743 pregnancies had been exposed to allergen immunotherapy (563 received SCIT specifically) three months before conception up until gestational week 22 [<a href="#rid55">55</a>]. Allergen-specific immunotherapy in pregnancy was not linked to congenital malformations or other adverse pregnancy outcomes.</p><p>Based on this information, it is recommended that SCIT be continued during pregnancy in patients already receiving it who also [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Appear to be deriving benefit</p><p class="bulletIndent1"><span class="glyph">●</span>Are not prone to systemic reactions to the immunotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Are receiving a maintenance dose or at least a dose that appears to be therapeutic for that patient</p><p></p><p>The dose is not increased during pregnancy, and some clinicians reduce the dose slightly in an effort to lower the risk of a systemic reaction further. If a pregnant patient has a systemic reaction to immunotherapy, treatment should be discontinued.</p><p>A similar approach is suggested for the use of sublingual immunotherapy (SLIT) during pregnancy. One study of 185 pregnancies did not find an increase in pregnancy complications in patients receiving SLIT compared with the general population or controls [<a href="#rid57">57</a>], and the Swedish cohort study described above included 204 women receiving SLIT during pregnancy with reassuring results [<a href="#rid55">55</a>]. SLIT should also not generally be initiated during pregnancy, but it can be continued if a patient is already receiving it and tolerating it well. (See  <a class="medical medical_review" href="/d/html/7538.html" rel="external">"Sublingual immunotherapy for allergic rhinitis and conjunctivitis: SLIT-tablets"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Rhinitis medicamentosa</span><span class="headingEndMark"> — </span>Rhinitis medicamentosa refers to rhinitis symptoms resulting from application of topical agents to the nasal mucosa. The most common precipitant is over-the-counter decongestant nasal sprays containing <a class="drug drug_general" data-topicid="10186" href="/d/drug information/10186.html" rel="external">oxymetazoline</a>. This adverse effect can be avoided by limiting use of these sprays to fewer than three days. (See <a class="local">'Decongestants'</a> above.)</p><p>Several days of nasal decongestant use leads to rebound nasal congestion as the medication wears off, prompting patients to increase the dose in an effort to obtain relief of symptoms and establishing a vicious cycle of nasal congestion and escalating medication use. Rhinitis medicamentosa may complicate viral respiratory infections or various causes of chronic rhinitis for which patients may resort to decongestant sprays.</p><p>Treatment involves discontinuation of the nasal decongestant and, in most cases, concomitant treatment with intranasal corticosteroids. Treatment options are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7533.html" rel="external">"An overview of rhinitis", section on 'Nasal decongestant sprays'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Acute bacterial rhinosinusitis</span><span class="headingEndMark"> — </span>One study found that acute bacterial rhinosinusitis was more common in pregnant than nonpregnant patients [<a href="#rid58">58</a>], although this was not confirmed in a large database study [<a href="#rid59">59</a>]. In the latter, a total of 103,129 pregnant patients were included who had live births during or between 2001 and 2010 and were continuously enrolled for the years before, during, and after the pregnancies. The proportions of patients treated with antibiotics for acute upper respiratory infection, with any encounter for acute sinusitis and with antibiotic treatment for sinusitis, were all greater in the year before and the year after pregnancy than during pregnancy. Sinusitis may still occur during pregnancy, and a high index of suspicion must be maintained for sinusitis during pregnancy because many pregnant females with sinusitis lack classic clinical findings [<a href="#rid58">58</a>]. The diagnosis and treatment of sinusitis in pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/4793.html" rel="external">"Approach to the pregnant patient with a respiratory infection", section on 'Acute sinusitis'</a> and  <a class="medical medical_review" href="/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">URTICARIA AND ANGIOEDEMA</span><span class="headingEndMark"> — </span>Urticaria, with or without angioedema, may occur during pregnancy because of any of the causes defined in the nonpregnant state. (See  <a class="medical medical_review" href="/d/html/8099.html" rel="external">"An overview of angioedema: Pathogenesis and causes"</a> and  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a>.)</p><p>Urticaria limited to pregnancy is rare, but affected patients may experience recurrences in subsequent pregnancies [<a href="#rid60">60,61</a>]. The pathogenesis of urticaria of pregnancy is unknown, although speculation includes allergic sensitization to endogenous hormones [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of urticaria is largely based on the appearance of the lesions. The diagnosis of acute and chronic urticaria is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a> and  <a class="medical medical_review" href="/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"</a>.)</p><p class="headingAnchor" id="H21405137"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Urticaria during pregnancy must be differentiated from other disorders that can mimic urticaria, as well as several of the dermatoses of pregnancy [<a href="#rid64">64</a>]. The differential diagnosis of urticaria (in any patient) is reviewed separately. (See  <a class="medical medical_review" href="/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Differential diagnosis'</a>.)</p><p>The dermatoses of pregnancy that are most likely to be mistaken for simple urticaria are:</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune progesterone dermatitis of pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritic urticarial papules and plaques of pregnancy (PUPPP), also known as polymorphic eruption of pregnancy (PEP)</p><p class="bulletIndent1"><span class="glyph">●</span>Other pruritic dermatoses of pregnancy, such as pemphigoid gestationis, prurigo of pregnancy, and cholestasis of pregnancy</p><p></p><p>Dermatologic conditions that affect pregnant persons are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/456.html" rel="external">"Maternal adaptations to pregnancy: Skin and related structures", section on 'Pruritus'</a> and  <a class="medical medical_review" href="/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>.)</p><p class="headingAnchor" id="H3968296456"><span class="h3">Autoimmune progesterone dermatitis of pregnancy</span><span class="headingEndMark"> — </span>A distinctive syndrome termed "autoimmune progesterone dermatitis of pregnancy" is characterized by a papulopustular eruption, transient arthritis, peripheral and tissue eosinophilia, spontaneous abortion, and delayed hypersensitivity to intradermal aqueous progesterone [<a href="#rid62">62</a>].</p><p>Autoimmune progesterone urticaria occurs in females, usually 7 to 10 days premenstrually. Progesterone-induced anaphylaxis has also been reported and is part of the spectrum of progestogen hypersensitivity. (See  <a class="medical medical_review" href="/d/html/13539.html" rel="external">"Progestogen hypersensitivity"</a>.)</p><p class="headingAnchor" id="H2277851586"><span class="h3">Pruritic urticarial papules and plaques of pregnancy</span><span class="headingEndMark"> — </span>PUPPP is an urticarial, pruritic eruption that develops in and around the abdominal striae in approximately 0.5 percent of pregnancies  (<a class="graphic graphic_picture graphicRef55164 graphicRef67980" href="/d/graphic/55164.html" rel="external">picture 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Polymorphic eruption of pregnancy'</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Laryngopathia gravidarum</span><span class="headingEndMark"> — </span>Laryngopathia gravidarum is a rare disorder that can mimic angioedema of the larynx. It is an acute or chronic, noninfectious, mildly inflammatory process of the laryngeal tissues in multigravida patients [<a href="#rid65">65</a>]. The pathogenesis remains speculative, but it may comprise several different entities. It has been attributed to an abnormal effect of pregnancy hormones on the laryngeal mucosa because of its rapid reduction after delivery.</p><p>The acute form occurs just before parturition, whereas the chronic form occurs earlier in pregnancy and may recur in subsequent pregnancies. Both forms spontaneously subside postpartum. Symptoms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive dyspnea (occasionally necessitating an artificial airway)</p><p class="bulletIndent1"><span class="glyph">●</span>Hoarseness</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfebrile sore throat and odynophagia</p><p class="bulletIndent1"><span class="glyph">●</span>Malaise</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Cough</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated white blood cell count and erythrocyte sedimentation rate (40 to 60 mm/hour)</p><p></p><p>The larynx and frequently the epiglottis demonstrate patchy, localized edema and congestion, but the aryepiglottic folds, arytenoids, vestibular region, and true vocal cords are unaffected. Microscopically, the surface epithelium and mucus glands are normal, but the submucosa appears edematous, being infiltrated with lymphocytes and plasma cells.</p><p class="headingAnchor" id="H23"><span class="h2">Management</span><span class="headingEndMark"> — </span>In patients with new-onset urticaria, identification and avoidance of offending agents or causes would ideally prevent urticaria or angioedema symptoms and obviate pharmacologic treatment. When symptomatic therapy is required, H1 antihistamines are recommended. Choice of agent is discussed above. (See <a class="local">'Oral antihistamines'</a> above.)</p><p>In patients with chronic urticaria (ie, recurrent urticaria that is present most days of the week for six weeks or longer), there are no identifiable triggers in most cases. Therapy begins with H1 antihistamines at standard doses, but it is not uncommon for patients to require higher doses (eg, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> 20 mg twice daily) to control symptoms. Higher doses have not been specifically studied in pregnancy.</p><p>The pharmacologic therapy of chronic urticaria in pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Pregnant or lactating women'</a>.)</p><p>Severe flares of acute and chronic urticaria are usually controlled with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, although oral glucocorticoids should be avoided during the first trimester, if possible. After that, prednisone is preferred over other oral glucocorticoid agents. The safety of prednisone in pregnancy and prednisone dosing in patients with chronic urticaria are also reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Systemic glucocorticoids for short-term control'</a>.)</p><p>Severe chronic urticaria can also be treated with <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, which has reassuring animal studies and for which some reassuring human pregnancy data exist [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Safety in pregnancy and lactation'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">ATOPIC DERMATITIS</span><span class="headingEndMark"> — </span>As with other atopic disorders, atopic dermatitis (AD) may worsen, remain the same, or improve with pregnancy [<a href="#rid67">67,68</a>]. In one study, most of the women whose symptoms worsened during pregnancy reported this trend by the 20<sup>th</sup> week [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Most pregnant persons with AD are aware of their disease before pregnancy since AD typically has its onset in infancy or early childhood. The most important clinical features essential to making the diagnosis of AD are [<a href="#rid64">64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic or recurring course</p><p class="bulletIndent1"><span class="glyph">●</span>Typical-appearing rash and distribution</p><p class="bulletIndent1"><span class="glyph">●</span>Atopy</p><p></p><p>The diagnosis of AD in pregnant patients is the same as in nonpregnant patients. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>AD during pregnancy must be differentiated from other pregnancy-related pruritic skin changes [<a href="#rid64">64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic pruritus (pruritus gravidarum) has its usual onset during the first trimester, and only excoriations are seen. It may be caused by a functional hepatic disturbance induced by estrogens. (See  <a class="medical medical_review" href="/d/html/456.html" rel="external">"Maternal adaptations to pregnancy: Skin and related structures", section on 'Pruritus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholestasis of pregnancy is a disorder presenting with pruritus of the palms and soles, generally without primary skin lesions (ie, other than excoriations) [<a href="#rid69">69</a>]. Elevation of serum bile acids triggers pruritus. Cholestasis of pregnancy is associated with an increased incidence of stillbirth, intrapartum fetal distress, and preterm labor, so it is important to make this diagnosis by assessing liver function in pregnant patients with unremitting pruritus and excoriations. (See  <a class="medical medical_review" href="/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a> and  <a class="medical medical_review" href="/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prurigo of pregnancy occurs in the second or third trimesters and is an erythematous papular eruption with excoriations, primarily localized to the anterior abdomen  (<a class="graphic graphic_picture graphicRef72147" href="/d/graphic/72147.html" rel="external">picture 2</a>). The mechanism has not been determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritic folliculitis of pregnancy usually occurs during the third trimester and presents with follicular papules and pustules on the trunk, which spread to the arms and legs. It usually resolves before delivery. (See  <a class="medical medical_review" href="/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Ideally, symptoms of AD should be optimally controlled before conception so that the medications can be tapered to the lowest effective dose in preparation for conception and early pregnancy.</p><p>Certain medications should be discontinued in advance of conception:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> for severe AD (used by either the female or male partner) should be discontinued at least three months prior to conception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoralens plus ultraviolet A (PUVA) should be stopped prior to conception, although a specific drug-free interval has not been established [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H28"><span class="h3">Emollients</span><span class="headingEndMark"> — </span>Treatment of AD during pregnancy should emphasize avoidance of triggering factors and maximize the use of emollients. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Emollients and moisturizers'</a>.)</p><p class="headingAnchor" id="H29"><span class="h3">Oral antihistamines</span><span class="headingEndMark"> — </span>Orally administered antihistamines should be used to control pruritus. <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">Loratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>, or <a class="drug drug_general" data-topicid="8860" href="/d/drug information/8860.html" rel="external">chlorpheniramine</a> are the preferred agents. Chlorpheniramine is sedating and can be helpful at bedtime. (See <a class="local">'Oral antihistamines'</a> above.)</p><p class="headingAnchor" id="H30"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>Data on the safety of low- or moderate-potency topical corticosteroids during pregnancy are reassuring [<a href="#rid71">71</a>]. In contrast, caution is warranted with potent or superpotent topical corticosteroids as use of these, particularly in the third trimester, has been associated with low birth weight [<a href="#rid72">72-74</a>].</p><p>When a topical corticosteroid is required for AD, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (0.5 to 2.5%, twice daily until symptoms are controlled) is a good initial choice, as it has a low potential for adrenal suppression [<a href="#rid9">9</a>]. Patients should be counseled to use stronger agents sparingly and only on those areas of the body that do not respond to weaker agents. There are no data upon which to recommend one particular medium-potency topical corticosteroid over another. If potent or superpotent topical corticosteroids are absolutely needed, the amount used should be kept to a minimum, and fetal growth should be monitored [<a href="#rid71">71</a>].</p><p>Studies of the safety of topical corticosteroids in pregnancy are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Use during pregnancy or lactation'</a>.)</p><p class="headingAnchor" id="H31"><span class="h3">Oral glucocorticoids</span><span class="headingEndMark"> — </span>For patients not responding to low- or medium-potency topical corticosteroids, oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> may be preferable to the use of significant amounts of more potent topical preparations. If possible, oral glucocorticoids should be avoided during the first trimester. After that, prednisone is preferred over other oral glucocorticoid agents. The safety of prednisone in pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H32"><span class="h3">Topical tacrolimus and pimecrolimus</span><span class="headingEndMark"> — </span>Reports of pregnancies in patients taking oral <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for preservation of organ transplants have been generally reassuring [<a href="#rid75">75</a>], although data on these agents are limited. Until more information is available, we suggest avoiding tacrolimus and <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> during pregnancy.</p><p class="headingAnchor" id="H4152613045"><span class="h3">Dupilumab</span><span class="headingEndMark"> — </span>The biologic <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, which binds to the alpha subunit of the interleukin (IL) 4 receptor to modulate both the IL-4 and IL-13 pathways, is effective in moderate-to-severe AD. However, although animal studies are reassuring, dupilumab use in human pregnancy has not been systematically studied. A review identified case reports evaluating the consequences in seven women and their offspring who were exposed to dupilumab during pregnancy [<a href="#rid76">76</a>]. Six women were on dupilumab for AD, whereas one was being treated for pemphigoid gestationis. All seven pregnancies led to live births. There was one premature birth, and another infant had low birth weight. (See  <a class="medical medical_review" href="/d/html/1726.html" rel="external">"Management of severe atopic dermatitis (eczema) in children", section on 'Dupilumab'</a>.)</p><p class="headingAnchor" id="H85047763"><span class="h3">JAK inhibitors</span><span class="headingEndMark"> — </span>These medications should be avoided during pregnancy. Two oral (<a class="drug drug_general" data-topicid="134831" href="/d/drug information/134831.html" rel="external">abrocitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>) and one topical (<a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>) Janus kinase (JAK) inhibitors are approved by the United States Food and Drug Administration (FDA) for the treatment of AD. According to the US FDA prescribing information, available human data are not sufficient to evaluate a drug-associated risk for adverse perinatal outcomes for any of these drugs. Based on animal studies, all of the drugs have the potential to adversely affect a developing fetus, at least at the high drug doses used.</p><p class="headingAnchor" id="H33"><span class="h2">Treatment of bacterial superinfection</span><span class="headingEndMark"> — </span>Infectious exacerbations of AD, generally secondary to <em>Staphylococcus aureus</em>, should be treated with penicillinase-resistant synthetic penicillins or <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> in patients who are allergic to penicillin. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16119.html" rel="external">"Patient education: Asthma and pregnancy (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16659.html" rel="external">"Patient education: Taking medicines during pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6719.html" rel="external">"Patient education: Asthma and pregnancy (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/368.html" rel="external">"Patient education: Anaphylaxis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/370.html" rel="external">"Patient education: Allergic rhinitis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/7637.html" rel="external">"Patient education: Contact dermatitis (including latex dermatitis) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluate prior to pregnancy when possible</strong> – Patients with significant allergic disease should ideally be evaluated <strong>before</strong> they become pregnant so that any skin testing, challenge procedures, or other exposures that might be necessary for definitive diagnosis can be safely performed and a plan for management during pregnancy can be formulated. (See <a class="local">'General approach to treating allergy in pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaphylaxis</strong> – The management of anaphylaxis during pregnancy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhinitis</strong> – Rhinitis is relatively common in pregnancy, and etiologies include pregnancy rhinitis, allergic rhinitis, sinusitis, and rhinitis medicamentosa. Nonpharmacologic measures, such as nasal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigation, can be helpful in all forms of rhinitis and should be recommended initially. (See <a class="local">'Rhinitis'</a> above and <a class="local">'Nondrug therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy rhinitis</strong> – Pregnancy rhinitis refers to nasal congestion and discharge lasting six weeks or more during pregnancy, in the absence of other causes of rhinitis, with resolution within two weeks of delivery. In most patients, pregnancy rhinitis can be managed with nonpharmacologic measures alone. (See <a class="local">'Pregnancy rhinitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allergic rhinitis</strong> – For pregnant patients with allergic rhinitis symptoms that have not responded sufficiently to nonpharmacologic measures, we suggest one or more of the following therapies  (<a class="graphic graphic_algorithm graphicRef134600" href="/d/graphic/134600.html" rel="external">algorithm 1</a>) (see <a class="local">'Allergic rhinitis/conjunctivitis'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intranasal <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> (one spray per nostril up to six times per day) for patients with mild symptoms (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Corticosteroid nasal sprays for patients with moderate-to-severe disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients in the first trimester, we suggest agents other than <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The oral H1 antihistamines <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, or <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a> in preference to other similar agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest <strong>avoiding</strong> oral decongestants in the first trimester of pregnancy and in any pregnant patient with hypertension (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). After the first trimester, <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> is the decongestant of choice, but we counsel patients to limit their use to occasional relief of severe nasal congestion. Decongestant nasal sprays should only be used in a limited manner as well since they may cause rebound congestion after a few days of use. Herbal therapies should also be avoided because they may not be regulated or monitored for contaminants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic urticaria</strong> – For pregnant patients with chronic urticaria, we suggest <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a> or <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Higher-than-usual doses, although not specifically studied in pregnancy, may be required. Severe flares can be treated with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, ideally after the first trimester. <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">Omalizumab</a> may be considered for recalcitrant chronic urticaria during pregnancy. (See <a class="local">'Urticaria and angioedema'</a> above and  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Pregnant or lactating women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis</strong> – The management of atopic dermatitis (AD) during pregnancy should emphasize avoidance of triggering factors, maximal use of emollients, and oral antihistamines as needed to control pruritus. (See <a class="local">'Atopic dermatitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with symptoms despite the above measures, we suggest topical <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (0.5 to 2.5%, applied to affected areas twice daily) until symptoms are controlled (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should be counseled to use moderate-potency topical corticosteroids sparingly and only on those areas of the body that do not respond to weaker agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During pregnancy, limited courses of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> may be preferable to the use of significant amounts of more potent topical corticosteroids. However, oral glucocorticoids should be avoided during the first trimester, if possible.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preliminary data on the use of <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> during pregnancy is reassuring. In contrast, Janus kinase (JAK) inhibitors should be avoided.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Scialli A, Lone A. Pregnancy effects of specific medications used to treat asthma and immunological diseases. In: Asthma and immunological diseases in pregnancy and early infancy, Schatz M, Zeiger RS, Claman HN (Eds), Marcel Dekker, New York 1998.</li><li><a class="nounderline abstract_t">Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978; 61:268.</a></li><li class="breakAll">Federal Register. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling: A Rule by the Food and Drug Administration on 12/04/2014. https://www.federalregister.gov/articles/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on January 23, 2015).</li><li><a class="nounderline abstract_t">Schatz M, Zeiger RS. Diagnosis and management of rhinitis during pregnancy. Allergy Proc 1988; 9:545.</a></li><li><a class="nounderline abstract_t">Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.</a></li><li><a class="nounderline abstract_t">Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician 2009; 80:1117.</a></li><li><a class="nounderline abstract_t">Garavello W, Somigliana E, Acaia B, et al. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. Int Arch Allergy Immunol 2010; 151:137.</a></li><li><a class="nounderline abstract_t">Eccles R. Nasal airflow in health and disease. Acta Otolaryngol 2000; 120:580.</a></li><li class="breakAll">Schatz M, Zeiger RS, Falkoff R, et al. Asthma and allergic diseases during pregnancy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Burks AW, et al (Eds), Mosby, St. Louis 2014. p.951.</li><li><a class="nounderline abstract_t">Turnbull GL, Rundell OH, Rayburn WF, et al. Managing pregnancy-related nocturnal nasal congestion. The external nasal dilator. J Reprod Med 1996; 41:897.</a></li><li><a class="nounderline abstract_t">Stroud RH, Wright ST, Calhoun KH. Nocturnal nasal congestion and nasal resistance. Laryngoscope 1999; 109:1450.</a></li><li><a class="nounderline abstract_t">Gani F, Braida A, Lombardi C, et al. Rhinitis in pregnancy. Eur Ann Allergy Clin Immunol 2003; 35:306.</a></li><li><a class="nounderline abstract_t">Ellegård EK. The etiology and management of pregnancy rhinitis. Am J Respir Med 2003; 2:469.</a></li><li><a class="nounderline abstract_t">Ellegård E, Hellgren M, Torén K, Karlsson G. The incidence of pregnancy rhinitis. Gynecol Obstet Invest 2000; 49:98.</a></li><li><a class="nounderline abstract_t">Ellegård EK. Pregnancy rhinitis. Immunol Allergy Clin North Am 2006; 26:119.</a></li><li><a class="nounderline abstract_t">Ellegård EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol 2004; 26:149.</a></li><li><a class="nounderline abstract_t">Ellegård EK, Karlsson NG, Ellegård LH. Rhinitis in the menstrual cycle, pregnancy, and some endocrine disorders. Clin Allergy Immunol 2007; 19:305.</a></li><li><a class="nounderline abstract_t">Ellegård E, Karlsson G. IgE-mediated reactions and hyperreactivity in pregnancy rhinitis. Arch Otolaryngol Head Neck Surg 1999; 125:1121.</a></li><li><a class="nounderline abstract_t">Ellegård EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol Allied Sci 2001; 26:394.</a></li><li><a class="nounderline abstract_t">Kircher S, Schatz M, Long L. Variables affecting asthma course during pregnancy. Ann Allergy Asthma Immunol 2002; 89:463.</a></li><li><a class="nounderline abstract_t">Somoskövi A, Bártfai Z, Tamási L, et al. Population-based case-control study of allergic rhinitis during pregnancy for birth outcomes. Eur J Obstet Gynecol Reprod Biol 2007; 131:21.</a></li><li><a class="nounderline abstract_t">Franklin KA, Holmgren PA, Jönsson F, et al. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest 2000; 117:137.</a></li><li><a class="nounderline abstract_t">Ayrım A, Keskin EA, Ozol D, et al. Influence of self-reported snoring and witnessed sleep apnea on gestational hypertension and fetal outcome in pregnancy. Arch Gynecol Obstet 2011; 283:195.</a></li><li><a class="nounderline abstract_t">O'Brien LM, Bullough AS, Owusu JT, et al. Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study. Am J Obstet Gynecol 2012; 207:487.e1.</a></li><li><a class="nounderline abstract_t">Powell H, Murphy VE, Hensley MJ, et al. Rhinitis in pregnant women with asthma is associated with poorer asthma control and quality of life. J Asthma 2015; 52:1023.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 23, 2010).</li><li><a class="nounderline abstract_t">Wilson J. Use of sodium cromoglycate during pregnancy. J Pharm Med 1982; 8:45.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115:34.</a></li><li><a class="nounderline abstract_t">Bérard A, Sheehy O, Kurzinger ML, Juhaeri J. Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. J Allergy Clin Immunol 2016; 138:97.</a></li><li><a class="nounderline abstract_t">Namazy JA, Schatz M. The safety of intranasal steroids during pregnancy: A good start. J Allergy Clin Immunol 2016; 138:105.</a></li><li><a class="nounderline abstract_t">Shaikh WA. A retrospective study on the safety of immunotherapy in pregnancy. Clin Exp Allergy 1993; 23:857.</a></li><li><a class="nounderline abstract_t">Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78:157.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111:1239.</a></li><li><a class="nounderline abstract_t">Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111:479.</a></li><li><a class="nounderline abstract_t">Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 2005; 28:707.</a></li><li><a class="nounderline abstract_t">Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146.</a></li><li><a class="nounderline abstract_t">Andersson NW, Torp-Pedersen C, Andersen JT. Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes. JAMA Pediatr 2020; 174:e201316.</a></li><li><a class="nounderline abstract_t">Yau WP, Mitchell AA, Lin KJ, et al. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol 2013; 178:198.</a></li><li class="breakAll">Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy, PSG Publishing, Littleton, MA 1977.</li><li><a class="nounderline abstract_t">Rayburn WF, Anderson JC, Smith CV, et al. Uterine and fetal Doppler flow changes from a single dose of a long-acting intranasal decongestant. Obstet Gynecol 1990; 76:180.</a></li><li><a class="nounderline abstract_t">Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45:361.</a></li><li><a class="nounderline abstract_t">Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54:84.</a></li><li><a class="nounderline abstract_t">Källén BA, Olausson PO. Use of oral decongestants during pregnancy and delivery outcome. Am J Obstet Gynecol 2006; 194:480.</a></li><li><a class="nounderline abstract_t">Smith CV, Rayburn WF, Anderson JC, et al. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. Obstet Gynecol 1990; 76:803.</a></li><li><a class="nounderline abstract_t">Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother 2007; 41:381.</a></li><li><a class="nounderline abstract_t">Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116.</a></li><li><a class="nounderline abstract_t">Meltzer EO, Ratner PH, McGraw T. Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study. J Allergy Clin Immunol Pract 2015; 3:702.</a></li><li><a class="nounderline abstract_t">Smith NT, Corbascio AN. The use and misuse of pressor agents. Anesthesiology 1970; 33:58.</a></li><li><a class="nounderline abstract_t">Cottle MK, Van Petten GR, van Muyden P. Effects of phenylephrine and sodium salicylate on maternal and fetal cardiovascular indices and blood oxygenation in sheep. Am J Obstet Gynecol 1982; 143:170.</a></li><li><a class="nounderline abstract_t">Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109:433.</a></li><li><a class="nounderline abstract_t">Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009; 65:1259.</a></li><li><a class="nounderline abstract_t">Nelsen LM, Shields KE, Cunningham ML, et al. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol 2012; 129:251.</a></li><li><a class="nounderline abstract_t">Cavero-Carbonell C, Vinkel-Hansen A, Rabanque-Hernández MJ, et al. Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark. Birth Defects Res 2017; 109:452.</a></li><li><a class="nounderline abstract_t">Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol 2017; 119:489.</a></li><li><a class="nounderline abstract_t">Mitselou N, Stephansson O, Melén E, Ludvigsson JF. Exposure to Allergen-Specific Immunotherapy in Pregnancy and Risk of Congenital Malformations and Other Adverse Pregnancy Outcomes. J Allergy Clin Immunol Pract 2022; 10:1635.</a></li><li><a class="nounderline abstract_t">Dombrowski MP, Schatz M, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol 2008; 111:457. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy 2012; 67:741.</a></li><li><a class="nounderline abstract_t">Sorri M, Hartikainen-Sorri AL, Kärjä J. Rhinitis during pregnancy. Rhinology 1980; 18:83.</a></li><li><a class="nounderline abstract_t">Namazy JA, Schatz M, Yang SJ, Chen W. Antibiotics for respiratory infections during pregnancy: prevalence and risk factors. J Allergy Clin Immunol Pract 2016; 4:1256.</a></li><li><a class="nounderline abstract_t">Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969; 81:588.</a></li><li><a class="nounderline abstract_t">Palmer GW, Claman HN. Pregnancy and immunology: selected aspects. Ann Allergy Asthma Immunol 2002; 89:350.</a></li><li><a class="nounderline abstract_t">Bierman SM. Autoimmune progesterone dermatitis of pregnancy. Arch Dermatol 1973; 107:896.</a></li><li><a class="nounderline abstract_t">Farah FS, Shbaklu Z. Autoimmune progesterone urticaria. J Allergy Clin Immunol 1971; 48:257.</a></li><li><a class="nounderline abstract_t">Boiko S, Zeiger R. Diagnosis and treatment of atopic dermatitis, urticaria, and angioedema during pregnancy. Immunol Allergy Clin North Am 2000; 20:839.</a></li><li><a class="nounderline abstract_t">Bhatia PL, Singh MS, Jha BK. Laryngopathia gravidarum. Ear Nose Throat J 1981; 60:408.</a></li><li><a class="nounderline abstract_t">Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020; 145:528.</a></li><li><a class="nounderline abstract_t">ROTH HL, KIERLAND RR. THE NATURAL HISTORY OF ATOPIC DERMATITIS. A 20-YEAR FOLLOW-UP STUDY. Arch Dermatol 1964; 89:209.</a></li><li><a class="nounderline abstract_t">Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol 1991; 125:59.</a></li><li><a class="nounderline abstract_t">Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.</a></li><li><a class="nounderline abstract_t">Weatherhead S, Robson SC, Reynolds NJ. Eczema in pregnancy. BMJ 2007; 335:152.</a></li><li><a class="nounderline abstract_t">Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011; 165:943.</a></li><li><a class="nounderline abstract_t">Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2009; :CD007346.</a></li><li><a class="nounderline abstract_t">Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol 2011; 131:884.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 2013; 149:1274.</a></li><li class="breakAll">Reprotox. www.reprotox.org (Accessed on August 31, 2010).</li><li><a class="nounderline abstract_t">Shakuntulla F, Chiarella SE. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract 2022; 10:3149.</a></li></ol></div><div id="topicVersionRevision">Topic 5552 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Scialli A, Lone A. Pregnancy effects of specific medications used to treat asthma and immunological diseases. In: Asthma and immunological diseases in pregnancy and early infancy, Schatz M, Zeiger RS, Claman HN (Eds), Marcel Dekker, New York 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632475" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The safety of immunotherapy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632475" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The safety of immunotherapy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2906890" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and management of rhinitis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892694" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical study and literature review of nasal irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19904896" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Saline nasal irrigation for upper respiratory conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752567" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039867" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nasal airflow in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039867" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nasal airflow in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8979203" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Managing pregnancy-related nocturnal nasal congestion. The external nasal dilator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499054" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nocturnal nasal congestion and nasal resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14653050" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rhinitis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14719986" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The etiology and management of pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671815" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The incidence of pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208461" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and pathogenetic characteristics of pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153022" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rhinitis in the menstrual cycle, pregnancy, and some endocrine disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522505" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : IgE-mediated reactions and hyperreactivity in pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11678947" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluticasone propionate aqueous nasal spray in pregnancy rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12452203" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Variables affecting asthma course during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442692" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Population-based case-control study of allergic rhinitis during pregnancy for birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631211" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Snoring, pregnancy-induced hypertension, and growth retardation of the fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20033421" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influence of self-reported snoring and witnessed sleep apnea on gestational hypertension and fetal outcome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999158" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365758" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rhinitis in pregnant women with asthma is associated with poorer asthma control and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365758" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rhinitis in pregnant women with asthma is associated with poorer asthma control and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of sodium cromoglycate during pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637545" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27045580" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27373328" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety of intranasal steroids during pregnancy: A good start.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780893" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A retrospective study on the safety of immunotherapy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048523" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antihistamines and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789223" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642825" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048356" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380668" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of antihistamine drugs in early pregnancy and delivery outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32478810" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23825167" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Use of decongestants during pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23825167" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of decongestants during pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196495" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Uterine and fetal Doppler flow changes from a single dose of a long-acting intranasal decongestant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1533958" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : First trimester maternal medication use in relation to gastroschisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8948544" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Maternal medications and environmental exposures as risk factors for gastroschisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458650" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of oral decongestants during pregnancy and delivery outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2216228" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264159" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230461" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143019" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4393417" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The use and misuse of pressor agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081329" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of phenylephrine and sodium salicylate on maternal and fetal cardiovascular indices and blood oxygenation in sheep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443241" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exogenous hormones and other drug exposures of children with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707749" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000568" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28398707" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29103802" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35487856" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exposure to Allergen-Specific Immunotherapy in Pregnancy and Risk of Congenital Malformations and Other Adverse Pregnancy Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18238988" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22486626" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A prospective study on the safety of sublingual immunotherapy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7403786" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rhinitis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27452887" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antibiotics for respiratory infections during pregnancy: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5801331" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Urticaria and angio-oedema. A review of 554 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392378" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pregnancy and immunology: selected aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4351124" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Autoimmune progesterone dermatitis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4398434" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Autoimmune progesterone urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnosis and treatment of atopic dermatitis, urticaria, and angioedema during pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7318714" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Laryngopathia gravidarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145939" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14081560" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : THE NATURAL HISTORY OF ATOPIC DERMATITIS. A 20-YEAR FOLLOW-UP STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1873205" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The influence of the menstrual cycle and pregnancy on atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17641349" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Eczema in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21729030" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evidence-based (S3) guideline on topical corticosteroids in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588425" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety of topical corticosteroids in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191410" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety of topical corticosteroids in pregnancy: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005903" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005903" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35987486" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Safety of Biologics for Atopic Diseases During Pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
